This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Cyto-megalovirus (CMV)	CMV glycoprotein B	<i>In vitro</i> and patient sample studies identified antibodies that could help prevent CMV. Anti-CMV glycoprotein B antibodies were identified in blood from CMV-infected patients. <i>In vitro</i> , the antibodies neutralized CMV infectivity at sub- μ g/ml concentrations. Next steps include a Phase I/IIa trial in hematopoietic cell transplant patients who are immunosuppressed. 4-Antibody AG is collaborating with the University of Erlangen-Nuremberg and has anti-CMV antibodies in preclinical development.	Patent application filed by 4-Antibody; licensing status undisclosed	Pöttsch, S. <i>et al. PLoS Pathog.</i> ; published online Aug. 11, 2011; doi:10.1371/journal.ppat.1002172 Contact: Michael Mach, University of Erlangen-Nuremberg, Germany e-mail: mlmach@viro.med.uni-erlangen.de
SciBX 4(34); doi:10.1038/scibx.2011.965 Published online Sept. 1, 2011				